mRNA Cancer Vaccine Shows ‘Landmark’ Results in Melanoma Trial

A personalized mRNA cancer vaccine from Moderna and Merck has shown promising results in a Phase 3 trial involving 1,137 people with high-risk melanoma. When paired with Merck’s immunotherapy Keytruda, intismeran autogene reduced the risk of melanoma returning and helped prevent the disease from spreading, according to interim findings reported August 19.

The trial compared the vaccine-and-Keytruda combination with Keytruda alone after patients had surgery to remove their melanoma. The companies said the study met its primary goal of improving recurrence-free survival and a key secondary goal involving distant metastasis-free survival. That makes the results a potential landmark for personalized cancer treatment: and the first positive Phase 3 result for an mRNA-based cancer therapy, according to company announcements and reporting by NBC News.

Unlike a preventive vaccine, intismeran autogene is designed for someone who has already been diagnosed with cancer. Researchers analyze tumor material to identify abnormal proteins, called neoantigens, then create an individualized mRNA treatment intended to train the immune system to recognize and attack remaining cancer cells. Keytruda is designed to help release immune-system “brakes.”

The exact size of the Phase 3 benefit has not yet been publicly released, and the findings have not been published in a peer-reviewed journal. The companies plan to present more data and seek regulatory approval. If that process moves forward, experts say the treatment could potentially become available as early as 2027.

For patients and families, the news is encouraging: but it is not a reason to change treatment plans independently. Anyone with a melanoma diagnosis should continue regular skin checks, follow-up appointments, and conversations with an oncology team. Brownstone Worldwide’s Wellness Watch will continue tracking what the next data releases and regulatory reviews show.

What questions do you have about personalized cancer vaccines, melanoma follow-up care, or the road from a promising trial to an approved treatment? Share your thoughts with the Brownstone community.